Zimmer Biomet (NYSE:ZBH) Issues Earnings Results, Beats Estimates By $0.02 EPS

Zimmer Biomet (NYSE:ZBH) issued its quarterly earnings data on Wednesday. The medical equipment provider reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.88 by $0.02, Zacks reports. The firm had revenue of $2 billion for the quarter, compared to analyst estimates of $2.01 billion. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The company’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same quarter last year, the firm earned $1.74 earnings per share. Zimmer Biomet updated its FY 2025 guidance to 8.100-8.300 EPS.

Zimmer Biomet Price Performance

NYSE:ZBH opened at $88.27 on Friday. The company has a fifty day moving average price of $100.50 and a 200 day moving average price of $97.54. Zimmer Biomet has a one year low of $85.33 and a one year high of $114.72. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96. The stock has a market cap of $17.49 billion, a P/E ratio of 21.48, a PEG ratio of 2.29 and a beta of 0.67.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, October 31st. Investors of record on Tuesday, September 30th were paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 1.1%. The ex-dividend date was Tuesday, September 30th. Zimmer Biomet’s dividend payout ratio is presently 23.36%.

Insider Buying and Selling at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,500 shares of Zimmer Biomet stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $104.15, for a total transaction of $156,225.00. Following the sale, the senior vice president directly owned 6,833 shares of the company’s stock, valued at $711,656.95. This trade represents a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.39% of the company’s stock.

Institutional Trading of Zimmer Biomet

Hedge funds have recently modified their holdings of the company. Headlands Technologies LLC acquired a new stake in shares of Zimmer Biomet during the 2nd quarter worth approximately $37,000. State of Wyoming bought a new position in Zimmer Biomet during the 2nd quarter valued at about $124,000. Federated Hermes Inc. boosted its holdings in shares of Zimmer Biomet by 129.2% in the 2nd quarter. Federated Hermes Inc. now owns 2,132 shares of the medical equipment provider’s stock worth $194,000 after acquiring an additional 1,202 shares in the last quarter. Brighton Jones LLC bought a new stake in shares of Zimmer Biomet during the fourth quarter worth $204,000. Finally, Chapman Financial Group LLC bought a new stake in Zimmer Biomet during the 2nd quarter worth about $218,000. Institutional investors own 88.89% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the stock. BTIG Research cut their price target on shares of Zimmer Biomet from $122.00 to $112.00 and set a “buy” rating on the stock in a report on Wednesday. Redburn Partners set a $130.00 price target on Zimmer Biomet in a research report on Thursday, September 18th. Evercore ISI lowered their price objective on Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating on the stock in a report on Tuesday, October 7th. Johnson Rice set a $112.00 target price on Zimmer Biomet in a report on Wednesday. Finally, Rothschild & Co Redburn began coverage on Zimmer Biomet in a report on Thursday, September 18th. They set a “buy” rating and a $130.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $109.42.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.